Martin C Burke

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10619223/publications.pdf

Version: 2024-02-01

186265 214800 3,519 50 28 47 citations h-index g-index papers 50 50 50 2070 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Efficacy and Safety of Appropriate Shocks and Antitachycardia Pacing in Transvenous and Subcutaneous Implantable Defibrillators: Analysis of All Appropriate Therapy in the PRAETORIAN Trial. Circulation, 2022, 145, 321-329.	1.6	28
2	Long-term performance of a novel communicating antitachycardia pacing–enabled leadless pacemakerÂand subcutaneous implantable cardioverter-defibrillator system: A comprehensive preclinical study. Heart Rhythm, 2022, , .	0.7	15
3	Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial. Circulation, 2021, 143, 7-17.	1.6	132
4	Outcomes of two versus three incision techniques: Results from the subcutaneous ICD postâ€approval study. Journal of Cardiovascular Electrophysiology, 2021, 32, 792-801.	1.7	7
5	1-Year Prospective Evaluation of Clinical Outcomes and Shocks. JACC: Clinical Electrophysiology, 2020, 6, 1537-1550.	3.2	24
6	Subcutaneous or Transvenous Defibrillator Therapy. New England Journal of Medicine, 2020, 383, 526-536.	27.0	278
7	Outcomes of subcutaneous implantable cardioverter-defibrillator in dialysis patients: Results from the S-ICD post-approval study. Heart Rhythm, 2020, 17, 1566-1574.	0.7	9
8	Feasibility of an Entirely Extracardiac, Minimally Invasive, Temporary Pacing System. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e007182.	4.8	9
9	Rationale and design of the PRAETORIAN-DFT trial: A prospective randomized CompArative trial of SubcutanEous ImplanTable CardiOverter-DefibrillatoR ImplANtation with and without DeFibrillation testing. American Heart Journal, 2019, 214, 167-174.	2.7	41
10	Understanding Outcomes with the EMBLEM S-ICD in Primary Prevention Patients with Low EF Study (UNTOUCHED): Clinical characteristics and perioperative results. Heart Rhythm, 2019, 16, 1636-1644.	0.7	48
11	Factors Associated With High-Voltage Impedance and Subcutaneous Implantable Defibrillator Ventricular Fibrillation Conversion Success. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e006665.	4.8	33
12	A novel tool to evaluate the implant position and predict defibrillation success of the subcutaneous implantable cardioverter-defibrillator: The PRAETORIAN score. Heart Rhythm, 2019, 16, 403-410.	0.7	94
13	Device orientation of a leadless pacemaker and subcutaneous implantable cardioverter-defibrillator in canine and human subjects and the effect on intrabody communication. Europace, 2018, 20, 1866-1871.	1.7	16
14	Impact of Body Mass Index on Safety andÂEfficacy of the Subcutaneous Implantable Cardioverter-Defibrillator. JACC: Clinical Electrophysiology, 2018, 4, 652-659.	3.2	34
15	Letter by Brouwer et al Regarding Article, "Ventricular Fibrillation Conversion Testing After Implantation of a Subcutaneous Implantable Cardioverter Defibrillator: Report From the National Cardiovascular Data Registry― Circulation, 2018, 138, 2970-2971.	1.6	0
16	Anesthesia for subcutaneous implantable cardioverterâ€defibrillator implantation: Perspectives from the clinical experience of a U.S. panel of physicians. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 807-816.	1.2	35
17	Prospective blinded evaluation of a novel sensing methodology designed to reduce inappropriate shocks by the subcutaneous implantable cardioverter-defibrillator. Heart Rhythm, 2018, 15, 1515-1522.	0.7	123
18	Performance of the subcutaneous implantable cardioverter-defibrillator in patients with a primary prevention indication with and without a reduced ejection fraction versus patients with a secondary prevention indication. Heart Rhythm, 2017, 14, 367-375.	0.7	30

#	Article	lF	Citations
19	Subcutaneous implantable cardioverter-defibrillator Post-Approval Study: Clinical characteristics and perioperative results. Heart Rhythm, 2017, 14, 1456-1463.	0.7	137
20	The Design of the Understanding Outcomes with the Sâ€ICD in Primary Prevention Patients with Low EF Study (UNTOUCHED). PACE - Pacing and Clinical Electrophysiology, 2017, 40, 1-8.	1.2	22
21	Acute and 3-Month Performance ofÂaÂCommunicating Leadless Antitachycardia Pacemaker and Subcutaneous Implantable Defibrillator. JACC: Clinical Electrophysiology, 2017, 3, 1487-1498.	3.2	57
22	Late Manifestation of Coronary Sinus and Left Atrial Perforation of a Left Ventricular Pacemaker Lead at Extraction. PACE - Pacing and Clinical Electrophysiology, 2016, 39, 502-506.	1.2	2
23	Outcomes in Patients With Congenital Heart Disease Receiving the Subcutaneous Implantable-Cardioverter Defibrillator. JACC: Clinical Electrophysiology, 2016, 2, 615-622.	3.2	26
24	Evaluation of subcutaneous ICD early performance in hypertrophic cardiomyopathy from the pooled EFFORTLESS and IDE cohorts. Heart Rhythm, 2016, 13, 1066-1074.	0.7	92
25	Infection and mortality after implantation of a subcutaneous ICD after transvenous ICD extraction. Heart Rhythm, 2016, 13, 157-164.	0.7	67
26	The learning curve associated with the introduction of the subcutaneous implantable defibrillator. Europace, 2016, 18, 1010-1015.	1.7	95
27	A New Algorithm to Reduce Inappropriate Therapy in the Sâ€ICD System. Journal of Cardiovascular Electrophysiology, 2015, 26, 417-423.	1.7	107
28	A farewell to subjectivity using multivariate analytical models to improve patient outcomes and lower costs. Heart Rhythm, 2015, 12, 1574-1575.	0.7	0
29	Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator. Journal of the American College of Cardiology, 2015, 65, 1605-1615.	2.8	458
30	3D Echocardiographic Location of Implantable Device Leads and Mechanism of Associated Tricuspid Regurgitation. JACC: Cardiovascular Imaging, 2014, 7, 337-347.	5.3	97
31	Impact of Implantable Transvenous Device Lead Location on Severity of Tricuspid Regurgitation. Journal of the American Society of Echocardiography, 2014, 27, 1164-1175.	2.8	44
32	Use of a discrimination algorithm to reduce inappropriate shocks with a subcutaneous implantable cardioverter-defibrillator. Heart Rhythm, 2014, 11, 1352-1358.	0.7	86
33	Mechanisms of Malfunction and Complications of the Subcutaneous ICD. Cardiac Electrophysiology Clinics, 2014, 6, 297-306.	1.7	0
34	Safety and Efficacy of a Totally Subcutaneous Implantable-Cardioverter Defibrillator. Circulation, 2013, 128, 944-953.	1.6	486
35	Ranolazine Safely Decreases Ventricular and Atrial Fibrillation in Timothy Syndrome (LQT8). PACE - Pacing and Clinical Electrophysiology, 2012, 35, e62-4.	1.2	35
36	Headâ€Toâ€Head Comparison of Arrhythmia Discrimination Performance of Subcutaneous and Transvenous ICD Arrhythmia Detection Algorithms: The START Study. Journal of Cardiovascular Electrophysiology, 2012, 23, 359-366.	1.7	192

#	Article	IF	CITATIONS
37	Medtronic Sprint Fidelis lead recall: Determining the initial 5-year management cost to Medicare. Heart Rhythm, 2011, 8, 1192-1197.	0.7	12
38	The infinite value in subcutaneous defibrillation. Heart Rhythm, 2010, 7, 699-700.	0.7	1
39	Percutaneous extraction of coronary sinus vein and branch leads. Heart Rhythm, 2008, 5, 491-495.	0.7	10
40	Postmortem Interrogation and Retrieval of Implantable Pacemakers and Defibrillators: A Survey of Morticians and Patients. Journal of Cardiovascular Electrophysiology, 2007, 18, 478-482.	1.7	58
41	Verapamil decreases ventricular tachyarrhythmias in a patient with Timothy syndrome (LQT8). Heart Rhythm, 2006, 3, 967-970.	0.7	64
42	Integration of cardiac imaging and electrophysiology during catheter ablation procedures for atrial fibrillation. Journal of Electrocardiology, 2006, 39, \$188-\$192.	0.9	19
43	Postmortem Analysis and Retrieval of Implantable Pacemakers and Defibrillators. New England Journal of Medicine, 2006, 354, 1649-1650.	27.0	11
44	Implications and Outcome of Permanent Coronary Sinus Lead Extraction and Reimplantation. Journal of Cardiovascular Electrophysiology, 2005, 16, 830-837.	1.7	57
45	Direct imaging of transvenous radiofrequency cardiac ablation using a steerable fiberoptic infrared endoscope. Heart Rhythm, 2005, 2, 1116-1121.	0.7	16
46	Defibrillation energy requirements using a left anterior chest cutaneous to subcutaneous shocking vector: Implications for a total subcutaneous implantable defibrillator. Heart Rhythm, 2005, 2, 1332-1338.	0.7	32
47	Analysis of electrocardiograms for subcutaneous monitors. Journal of Electrocardiology, 2003, 36, 227-232.	0.9	7
48	Atypical Atrial Flutter Originating in the Right Atrial Free Wall. Circulation, 2000, 101, 270-279.	1.6	107
49	Frozen shoulder syndrome associated with subpectoral defibrillator implantation. Journal of Interventional Cardiac Electrophysiology, 1999, 3, 253-256.	1.3	15
50	Atrial Fibrillation After Radiofrequency Ablation of Type I Atrial Flutter. Circulation, 1998, 98, 315-322.	1.6	151